Navigation Links
Parent Project Muscular Dystrophy Awards End Duchenne Grant to University of Pennsylvania's Dr. Tejvir S. Khurana
Date:9/22/2011

HACKENSACK, N.J., Sept. 22, 2011 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced that it has awarded Tejvir S. Khurana, MD, PhD, Professor of Physiology at the University of Pennsylvania and Pennsylvania Muscle Institute an End Duchenne Grant for $98,000.

(Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO)

Dr. Khurana is a molecular geneticist / physiologist and highly accomplished scientist who discovered the utrophin protein (originally named Dystrophin-related protein). This bridge funding will allow Dr. Khurana the resources to continue work to upregulate utrophin and correct the underlying defect in mdx muscle with the objective of translation to the clinic.

Duchenne muscular dystrophy occurs when the dystrophin protein is missing or not functioning. Utrophin is a kind of molecular cousin to dystrophin that can compensate for the lack of dystrophin when it is present in larger than normal quantities.

The End Duchenne Grant Award Program was created by PPMD in partnership with the National Institutes of Health (NIH) in an effort to ensure continuation of promising Duchenne research and translation to human studies. The End Duchenne Grant Award Program is a bridge grant provided by PPMD to selected research projects that receive scores beyond the current funding paylines of the NIH Institutes and Centers supporting Duchenne research.  To date, PPMD has awarded over $1 million through this program. All past End Duchenne Grant recipients, thus far, have gone on to receive NIH funding.

Explains Pat Furlong, Founding President and CEO, "With its research budget growing tighter each year, the NIH can fund only a fraction of the many promising applications it receives.   Currently, only those grants which score in the top percentiles are able to be funded. We are thrilled that we have been able to step in, since the launch of the End Duchenne Grant Program in 2009, and provide the bridge funding needed to continue critical research like Dr. Khurana's."

The End Duchenne Grant Award Program represents the first Duchenne specific bridging program and the first ongoing bridge funding program to be presented in the rare disease category. As a collaborative effort with the NIH, the selection strategy behind this award is very different than any other private research investment in Duchenne, yet the goal of this award remains consistent with all of PPMD's research initiatives:  to advance promising research which will impact this generation affected by Duchenne.

Dr. Khurana looks forward to continuing his work upregulating utrophin and thanks the organization for their financial support: "Parent Project Muscular Dystrophy and University of Pennsylvania have a long history together. Receiving this End Duchenne Grant is a great affirmation that the Duchenne community believes in the work we are doing here. We are hopeful that this therapy will change the progression of Duchenne and help extend the lifespan and quality of life for all patients living with the disorder."

To learn more about Parent Project Muscular Dystrophy's End Duchenne Grant Award Program, visit ParentProjectMD.org.

About Parent Project Muscular Dystrophy

Duchenne is a fatal genetic disorder that slowly robs young men of their muscle strength. Parent Project Muscular Dystrophy's  mission is to end Duchenne.

We invest deeply in treatments for this generation of young men affected by Duchenne and in research that will benefit future generations. We advocate in Washington, DC, and have secured hundreds of millions of dollars in funding. We demand optimal care, and we strengthen, unite, and educate the global Duchenne community.

Everything we do -- and everything we have done since our founding in 1994 -- helps boys with Duchenne live longer, stronger lives. We will not rest until every young man has a treatment to end Duchenne. Go to www.ParentProjectMD.org for more information or to learn how you can support our efforts and help families affected by Duchenne.


'/>"/>
SOURCE Parent Project Muscular Dystrophy
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. USC researchers print dense lattice of transparent nanotube transistors on flexible base
2. Gender-Selection Technique Embraced for Hopeful Parents
3. First-Ever Egg Donor Web Portal Becomes One of The Largest Resources for Aspiring Parents in the U.S.
4. NIST scientists address wrinkles in transparent film development
5. Scientists produce transparent, light-harvesting material
6. Transparent conductive material could lead to power-generating windows
7. Parenteral Depots Offer $8 Billion of Reformulation Opportunities and a Strong Competitive Edge in Crowded Pharmaceutical Space
8. UV-transparent coating for image sensors
9. Parents Guide to Cord Blood Foundation Launches Nations First Searchable Map of U.S. Sites for Donating Umbilical Cord Blood
10. Poplar Healthcare Forms Parent Company, Launches New Web Site
11. enLiven Yogurt Sponsors "Back to School Grocery Giveaway" to Keep Parents and Kids Eating Healthy Foods this Fall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ORLANDO, Fla. , Feb. 20, 2017 /PRNewswire/ ... (HIMSS) conference in Orlando , ... new offerings, collaborators and clients. IBM Chairman, President ... the HIMSS17 opening keynote address today from 8:30-10 ... www.ibm.com/watson/health , and ibm.com/industries/healthcare. Her remarks examine ...
(Date:2/18/2017)... MONTREAL , February 18, 2017 ... von intrazellulären Zytokinen bei adoptiven Zelltherapie-Studien, Poster legt metaproteomische ... ... Biosciences Inc. heute bekanntgab, wird Dr. Yoav Peretz ... Methoden in der Entwicklung von Assays zum Nachweis intrazellulärer ...
(Date:2/18/2017)... Research and Markets has announced the addition of the ... offering. ... report provides separate comprehensive analytics for the US, Japan ... Annual estimates and forecasts are provided for the period 2015 through ... Market data and analytics are derived from primary and secondary research. ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology:
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):